- Home
- DIBS vs ANL Comparison
DIBS vs ANL Comparison
Compare DIBS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- ANL
- Stock Information
- Founded
- DIBS 2000
- ANL 2004
- Country
- DIBS United States
- ANL Cayman Islands
- Employees
- DIBS N/A
- ANL N/A
- Industry
- DIBS Catalog/Specialty Distribution
- ANL
- Sector
- DIBS Consumer Discretionary
- ANL
- Exchange
- DIBS Nasdaq
- ANL Nasdaq
- Market Cap
- DIBS 88.1M
- ANL 73.8M
- IPO Year
- DIBS 2021
- ANL 2023
- Fundamental
- Price
- DIBS $2.49
- ANL $1.59
- Analyst Decision
- DIBS Hold
- ANL Buy
- Analyst Count
- DIBS 1
- ANL 2
- Target Price
- DIBS N/A
- ANL N/A
- AVG Volume (30 Days)
- DIBS 131.6K
- ANL 11.0K
- Earning Date
- DIBS 05-09-2025
- ANL 06-13-2025
- Dividend Yield
- DIBS N/A
- ANL N/A
- EPS Growth
- DIBS N/A
- ANL N/A
- EPS
- DIBS N/A
- ANL N/A
- Revenue
- DIBS $88,740,000.00
- ANL N/A
- Revenue This Year
- DIBS $3.23
- ANL N/A
- Revenue Next Year
- DIBS $5.90
- ANL N/A
- P/E Ratio
- DIBS N/A
- ANL N/A
- Revenue Growth
- DIBS 4.93
- ANL N/A
- 52 Week Low
- DIBS $2.30
- ANL $1.10
- 52 Week High
- DIBS $5.80
- ANL $8.24
- Technical
- Relative Strength Index (RSI)
- DIBS 46.83
- ANL 42.48
- Support Level
- DIBS $2.39
- ANL $1.71
- Resistance Level
- DIBS $2.56
- ANL $2.10
- Average True Range (ATR)
- DIBS 0.14
- ANL 0.08
- MACD
- DIBS 0.01
- ANL 0.00
- Stochastic Oscillator
- DIBS 40.00
- ANL 0.00
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.